BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 17, Issue 10
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (198)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.
Item 
Count 
PDF12
HTML73
Figures (1-1)15
Tables (1-4)17
 Sum=117
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse17
Download41
 Sum=58
Oct 15, 2025 (publication date) through Oct 25, 2025
Times Cited of This Article
  • Times Cited  (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. Oct 15, 2025; 17(10): 110415
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.110415
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Current treatment approach for biliary tract cancer. A schematic overview of the current treatment approach for biliary tract cancer. FFX: FOLFOX; FGFR-I: Fibroblast growth factor receptor inhibitor; GC: Gemcitabine + cisplatin; GCS: Gemcitabine + cisplatin + S1; GS: Gemcitabine + S1; ICI: Immune checkpoint inhibitor; IGH-I: Isocitrate dehydrogenase inhibitor.
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345